EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.
Document Type
Article
Publication Date
3-15-2020
Keywords
JGM
JAX Source
Clin Cancer Res 2020 Mar 15; 26(6):1395-1407
Volume
26
Issue
6
First Page
1395
Last Page
1407
ISSN
1078-0432
PMID
31852834
DOI
https://doi.org/10.1158/1078-0432.CCR-19-2549
Abstract
PURPOSE: Exploration of novel strategies to extend the benefit of PARP inhibitors beyond
EXPERIMENTAL DESIGN: Selective sensitivity to the PARP inhibitor talazoparib was screened and validated in two sets [test set (
RESULTS:
CONCLUSIONS:
Recommended Citation
Wu S,
Gao F,
Zheng S,
Zhang C,
Martinez-Ledesma E,
Ezhilarasan R,
Ding J,
Li X,
Feng N,
Multani A,
Sulman E,
Verhaak R,
de Groot J,
Heffernan T,
Yung W,
Koul D.
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res 2020 Mar 15; 26(6):1395-1407